Armistice Capital LLC Invests $12.92 Million in KalVista Pharmaceuticals, Inc. $KALV

Armistice Capital LLC purchased a new position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) during the fourth quarter, Holdings Channel reports. The institutional investor purchased 800,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $12,920,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. grew its stake in KalVista Pharmaceuticals by 3.7% in the third quarter. Vanguard Group Inc. now owns 2,501,119 shares of the specialty pharmaceutical company’s stock valued at $30,464,000 after purchasing an additional 88,720 shares during the last quarter. Tudor Investment Corp ET AL acquired a new stake in KalVista Pharmaceuticals in the third quarter worth about $24,360,000. State Street Corp boosted its holdings in KalVista Pharmaceuticals by 21.3% in the fourth quarter. State Street Corp now owns 1,911,691 shares of the specialty pharmaceutical company’s stock worth $30,874,000 after acquiring an additional 336,195 shares in the last quarter. Parkman Healthcare Partners LLC lifted its holdings in shares of KalVista Pharmaceuticals by 155.5% during the third quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock worth $21,132,000 after purchasing an additional 1,055,940 shares during the period. Finally, Schroder Investment Management Group lifted its holdings in shares of KalVista Pharmaceuticals by 1.1% during the fourth quarter. Schroder Investment Management Group now owns 1,171,755 shares of the specialty pharmaceutical company’s stock worth $18,924,000 after purchasing an additional 13,298 shares during the period.

Insider Activity

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par sold 174,645 shares of the stock in a transaction dated Wednesday, March 25th. The stock was sold at an average price of $16.95, for a total value of $2,960,232.75. Following the sale, the insider owned 5,129,340 shares of the company’s stock, valued at $86,942,313. This trade represents a 3.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Paul K. Audhya sold 2,686 shares of the stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $20.22, for a total value of $54,310.92. Following the completion of the sale, the insider directly owned 142,547 shares in the company, valued at $2,882,300.34. This represents a 1.85% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 254,602 shares of company stock worth $4,656,670 in the last quarter. Insiders own 4.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on KALV shares. Wall Street Zen raised KalVista Pharmaceuticals to a “hold” rating in a report on Saturday, June 13th. JonesTrading cut KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 30th. Leerink Partners cut KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Stifel Nicolaus boosted their price target on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 21st. Three analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $30.60.

KalVista Pharmaceuticals Stock Performance

Shares of KalVista Pharmaceuticals stock opened at $27.00 on Thursday. KalVista Pharmaceuticals, Inc. has a 52 week low of $9.83 and a 52 week high of $27.00. The business’s fifty day simple moving average is $24.58 and its 200-day simple moving average is $19.11. The firm has a market cap of $1.44 billion, a PE ratio of -7.80 and a beta of -0.12. The company has a quick ratio of 5.10, a current ratio of 5.17 and a debt-to-equity ratio of 8.18.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The firm had revenue of $40.86 million during the quarter, compared to analyst estimates of $39.03 million. Equities analysts forecast that KalVista Pharmaceuticals, Inc. will post -1.19 earnings per share for the current year.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.